Ubs Group Ag Spero Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 17,529 shares of SPRO stock, worth $20,684. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,529

Previous 331 5195.77%

Holding current value

$20,684

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.19 - $1.5 $20,465 - $25,797	17,198 Added 5195.77%	17,529 $23,000
Q2 2024 Aug 13, 2024	SELL	$1.27 - $1.8 $6,854 - $9,714	-5,397 Reduced 94.22%	331 $0
Q1 2024 May 13, 2024	BUY	$1.35 - $1.79 $7,288 - $9,664	5,399 Added 1641.03%	5,728 $9,000
Q4 2023 Feb 09, 2024	SELL	$1.0 - $1.47 $26,806 - $39,404	-26,806 Reduced 98.79%	329 $0
Q3 2023 Nov 09, 2023	BUY	$1.2 - $1.63 $76 - $104	64 Added 0.24%	27,135 $32,000
Q2 2023 Aug 11, 2023	SELL	$1.42 - $1.95 $20,521 - $28,181	-14,452 Reduced 34.8%	27,071 $39,000
Q1 2023 May 12, 2023	SELL	$1.35 - $2.0 $5,614 - $8,318	-4,159 Reduced 9.1%	41,523 $60,000
Q4 2022 Feb 08, 2023	BUY	$1.55 - $2.12 $35,299 - $48,280	22,774 Added 99.42%	45,682 $79,000
Q3 2022 Nov 10, 2022	BUY	$0.68 - $2.2 $15,064 - $48,736	22,153 Added 2934.17%	22,908 $46,000
Q1 2022 May 16, 2022	SELL	$7.87 - $15.15 $254,413 - $489,754	-32,327 Reduced 97.72%	755 $7,000
Q4 2021 Feb 14, 2022	BUY	$13.09 - $18.77 $55,763 - $79,960	4,260 Added 14.78%	33,082 $529,000
Q3 2021 Nov 15, 2021	BUY	$13.03 - $19.51 $350,884 - $525,384	26,929 Added 1422.56%	28,822 $530,000
Q2 2021 Aug 13, 2021	SELL	$12.22 - $15.79 $356,017 - $460,025	-29,134 Reduced 93.9%	1,893 $27,000
Q1 2021 May 12, 2021	BUY	$13.23 - $21.48 $220,676 - $358,286	16,680 Added 116.26%	31,027 $456,000
Q4 2020 Feb 11, 2021	BUY	$11.65 - $22.07 $161,317 - $305,603	13,847 Added 2769.4%	14,347 $278,000
Q3 2020 Nov 12, 2020	SELL	$8.96 - $14.12 $48,849 - $76,982	-5,452 Reduced 91.6%	500 $6,000
Q2 2020 Jul 31, 2020	SELL	$7.27 - $14.18 $22,108 - $43,121	-3,041 Reduced 33.82%	5,952 $80,000
Q1 2020 May 01, 2020	SELL	$5.27 - $10.41 $27,793 - $54,902	-5,274 Reduced 36.97%	8,993 $73,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $30,423 - $39,106	3,216 Added 29.1%	14,267 $137,000
Q3 2019 Nov 14, 2019	SELL	$9.01 - $12.55 $6,766 - $9,425	-751 Reduced 6.36%	11,051 $117,000
Q2 2019 Aug 14, 2019	BUY	$10.25 - $14.36 $120,970 - $169,476	11,802 New	11,802 $136,000
Q1 2019 May 14, 2019	SELL	$6.26 - $13.31 $20,032 - $42,592	-3,200 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$5.69 - $11.28 $4,785 - $9,486	841 Added 35.65%	3,200 $20,000
Q3 2018 Nov 14, 2018	BUY	$9.69 - $17.79 $13,701 - $25,155	1,414 Added 149.63%	2,359 $25,000
Q2 2018 Aug 14, 2018	BUY	$10.41 - $17.85 $4,674 - $8,014	449 Added 90.52%	945 $13,000
Q1 2018 May 15, 2018	BUY	$9.96 - $14.61 $3,665 - $5,376	368 Added 287.5%	496 $7,000
Q4 2017 Feb 14, 2018	BUY	$10.43 - $14.75 $1,335 - $1,888	128	128 $1,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

13.9M

Call Options Held

200

Put Options Held

200

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $41.4M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account